Acadia Pharmaceuticals Inc. (ACAD) — QMA analysis
Sector: Healthcare · Market cap: $3.9B · Price: $19.73 · Data as of 2026-10-23
A composite score of 47/100 places Acadia Pharmaceuticals Inc. in the neutral band, higher score than 62% of 22,734 tracked stocks. The highest-scoring layer is Fundamental value; the lowest is Off-exchange trading (FINRA) / large flows.
What 6 data layers say about ACAD
The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.
| Layer | Score |
|---|---|
| Fundamental value (FVS) | 82/100 |
| Technical trend (TSS) | 49/100 |
| Relative strength (RS) | 29/100 |
| Momentum (USS) | 35/100 |
| Insider activity (IAS) | 21/100 |
| Off-exchange trading (FINRA) / large flows (WHS) | 16/100 |
What does the QMA model currently show for Acadia Pharmaceuticals Inc.?
The composite score is a research starting point, not an instruction. What matters is layer confluence — whether the layers point in the same direction.
For ACAD the layers diverge — some score high (Fundamental value), others low (Off-exchange trading (FINRA) / large flows). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.
ACAD insider & smart money activity
Over the recent period we record 2 reported insider purchases and 7 sales for ACAD: predominance of reported sales (by dollar value). A description of the data layer, not an instruction.
How ACAD compares
Similar stocks from the same sector:
Frequently asked questions
What is the composite score for ACAD stock?
47/100 (C) — Data as of 2026-10-23.
Are insiders buying ACAD stock?
Over the recent period, reported: purchases 2, sales 7 (purchases $359K, sales $1.27M). Insider activity: predominance of reported sales (by dollar value) — a description of reported data, not a trade instruction.
Where can I see live ACAD data?
Live ACAD data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.
Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.
⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.
Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]